Real-world monitoring of platelet counts among patients with epithelial ovarian cancer receiving first-line maintenance niraparib in the United States: the ACTIV1ZE study

被引：0
|
作者：
Musa, Fernanda [1 ]
Boyle, Tirza [2 ]
Lim, Jonathan [2 ]
Moore, Julia [2 ]
Schilder, Jeanne [3 ]
Hurteau, Jean [4 ]
Golembesky, Amanda [5 ]
Landrum, Lisa [6 ]
机构：
[1] Swedish Canc Inst, Seattle, WA USA
[2] GSK, Upper Providence, PA USA
[3] GSK, Philadelphia, PA USA
[4] GSK, Waltham, MA USA
[5] GSK, Durham, NC USA
[6] Indiana Univ, Hlth Simon Canc Ctr, Indianapolis, IN USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.74
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR032/#594
引用
收藏
页码：A56 / A57
页数：2
相关论文
共 50 条
  • [1] Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer
    Salani, Ritu
    Boyle, Tirza Areli Calderon
    Lim, Jonathan
    Schilder, Jeanne M.
    Hurteau, Jean A.
    Perhanidis, Jessica
    Golembesky, Amanda
    Backes, Floor J.
    FUTURE ONCOLOGY, 2025, 21 (02) : 213 - 219
  • [2] Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study
    Chase, Dana M.
    Hanna, Maya
    Lim, Jonathan T.
    Boyle, Tirza Areli Calderon
    Guinter, Mark
    Richey, Madeline
    Patel, Khilna
    Schilder, Jeanne M.
    Hurteau, Jean A.
    Golembesky, Amanda K.
    ONCOLOGY AND THERAPY, 2025, 13 (01) : 253 - 262
  • [3] Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer.
    Vasudevan, Anupama
    English, Sandy
    Gart, Mike
    Oladipo, Taofikat
    Hartman, John
    Iadeluca, Laura L.
    Kudrik, Fred J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database
    Liu, Jinan
    Thaker, Premal
    Song, Jinlin
    Kalilani, Linda
    Guo, Helen
    Wu, Eric
    Hurteau, Jean
    Chan, John
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S180 - S180
  • [5] Real-world experience with a first-line niraparib maintenance monotherapy for advanced ovarian carcinoma
    Gregoric, Brigita
    Skof, Erik
    Skrbinc, Breda
    Geltar, Ana
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A220 - A220
  • [6] Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study
    Thaker, Premal H.
    Boyle, Tirza
    Perhanidis, Jessica
    Burns, Sara
    Lim, Jonathan
    Hartman, John
    Kalilani, Linda
    Schilder, Jeanne
    Hurteau, Jean
    Golembesky, Amanda
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S199 - S200
  • [7] Outcomes of niraparib first-line maintenance among patients with BRCA wild-type advanced ovarian cancer in a real-world clinical setting
    Kupets, Rachel
    Piedimonte, Sabrina
    Clarfield, Lauren
    Manley, Mollie
    Peragine, Christine
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S265 - S266
  • [8] Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study
    Thaker, Premal H.
    Boyle, Tirza Areli Calderon
    Burns, Sara
    Lim, Jonathan
    Hartman, John
    Kalilani, Linda, V
    Schilder, Jeanne M.
    Hurteau, Jean A.
    Golembesky, Amanda K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024,
  • [9] Efficacy and safety of niraparib as first-line maintenance treatment for patients with advanced ovarian cancer: Real-world data from a multicenter study in China
    Shen, Yang
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S317 - S317
  • [10] Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
    Minmin Zhao
    Shanhu Qiu
    Xin Wu
    Pengcheng Miao
    Zhi Jiang
    Tao Zhu
    Xizhong Xu
    Yanling Zhu
    Bei Zhang
    Donglan Yuan
    Yang Zhang
    Wei Sun
    Aiqin He
    Min Zhao
    Wenjie Hou
    Yingli Zhang
    Zhuyan Shao
    Meiqun Jia
    Mei Li
    Jun Chen
    Jingcheng Xu
    Bingwei Chen
    Ying Zhou
    Yang Shen
    Targeted Oncology, 2023, 18 : 869 - 883
12345